Full Prescribing
Information
About Naropin > Benefits vs Bupivacaine > Motor Function
Motor Function
Choose NAROPIN® for Faster Return of Motor Function1-9
The low lipid solubility of NAROPIN gives it more selectivity for C sensory fibers, resulting in less interference with A motor fibers, which enables a faster return of motor function.10
Chart 1: 8 to 10 Hours Faster Return of Motor Function Following Total Knee Replacement1
At equal concentrations (0.5%), NAROPIN patients experienced significantly faster return of motor function following sciatic-femoral block for total knee replacement surgery vs bupivacaine.1
Chart 2: 5 to 9 Hours Faster Return of Motor Function Following Lower Arm Surgery2
At equal concentrations, patients treated with NAROPIN who achieved partial motor block regained motor function at the hand and wrist significantly faster than patients treated with bupivacaine.2
Chart 3: 66 Minutes Faster Return of Motor Function Following Lower Extremity Surgery3
NAROPIN patients experienced significantly faster return of motor function following lower extremity surgeries.3
NAROPIN is indicated for the production of local or regional anesthesia for surgery and for acute pain management.
Back to Top
Less Motor Block Facilitates Improved Outcomes4,5
Less pronounced motor block with NAROPIN may enable more active participation and more effective bearing down, resulting in more spontaneous vaginal deliveries and potentially less instrumented deliveries.4
Chart 1: 58% Spontaneous Vaginal Deliveries With NAROPIN vs 49% With Bupivacaine4
Significantly more spontaneous vaginal deliveries occurred with NAROPIN in labor and delivery epidurals.4
Chart 2: 32% Fewer Instrumented Deliveries4
Epidural analgesia with NAROPIN significantly decreased the incidence of instrumented delivery with forceps and vacuum extraction vs bupivacaine in labor and delivery epidurals.4
Chart 3: 1.2 Hours Faster Return of Motor Function Following Caesarean Sections8
At equal concentrations, patients receiving NAROPIN have a significantly faster return of motor function following C-sections when compared with those receiving bupivacaine.8
Chart 4: Patients Recovered Motor Function 96 Minutes Faster After Complete Motor Paralysis Following Caesarean Section9
The duration of degree 4 motor block was significantly shorter with NAROPIN.9
Chart 5: 51% of Mothers Treated With NAROPIN Had No Motor Block4
Among mothers who received NAROPIN 0.25%, 51% had no measurable motor block during the entire study vs 42% of mothers who received bupivacaine 0.25% in labor and delivery epidurals.4
Back to Top
NAROPIN is indicated for the production of local or regional anesthesia for surgery and for acute pain management.
1. Beaulieu P, Babin D, Hemmerling T. The pharmacodynamics of ropivacaine and bupivacaine in combined sciatic and femoral nerve blocks for total knee arthroplasty. Anesth Analg. 2006;103:768-774.
2. McGlade DP, Kalpokas MV, Mooney PH, et al. A comparison of 0.5% ropivacaine and 0.5% bupivacaine for axillary brachial plexus anaesthesia. Anaesth Intensive Care. 1998;26:515-520.
3. Morrison LM, Emanuelsson BM, McClure JH, et al. Efficacy and kinetics of extradural ropivacaine: comparison with bupivacaine. Br J Anaesth. 1994;72:164-169.
4. Writer WDR, Stienstra R, Eddleston JM, et al. Neonatal outcome and mode of delivery after epidural analgesia for labour with ropivacaine and bupivacaine: a prospective meta-analysis. Br J Anaesth. 1998;81:713-717.
5. NAROPIN Prescribing Information. Data on file.
6. Aşik I, Göktuğ A, Gülay I, Alkiş N, Uysalel A. Comparison of bupivacaine 0.2% and ropivacaine 0.2% combined with fentanyl for epidural analgesia during labour. Eur J Anaesthesiol. 2002;19:263-270.
7. Datta S, Camann W, Bader A, VanderBurgh L. Clinical effects and maternal and fetal plasma concentrations of epidural ropivacaine versus bupivacaine for cesarean section. Anesthesiology. 1995;82:1346-1352.
8. Griffin RP, Reynolds F. Extradural anaesthesia for caesarean section: a double-blind comparison of 0.5% ropivacaine with 0.5% bupivacaine. Br J Anaesth. 1995;74:512-516.
9. Crosby E, Sandler A, Finucane B, et al. Comparison of epidural anaesthesia with ropivacaine 0.5% and bupivacaine 0.5% for caesarian section. Can J Anaesth. 1998;45:1066-1071.
10. Hansen T. Ropivacaine: a pharmacologic review. Expert Rev Neurother. 2004;4:781-791.
Important Safety Information
Using NAROPIN beyond recommended doses to increase motor block or duration of sensory block may negate its favorable cardiovascular advantages, in the event that an inadvertent intravascular injection occurs.
Like all amide-type local anesthetics, NAROPIN may be associated with adverse reactions. In clinical trials, side effects were mild and transient and may reflect the procedures, patient health status, and/or other medications used. Adverse events reported at a rate of ≥5%: hypotension, nausea, vomiting, bradycardia, fever, pain, postoperative complications, anemia, paresthesia, headache, pruritus, and back pain.
New Safety Information
There have been adverse event reports of chondrolysis in patients receiving intra-articular infusions of local anesthetics following arthroscopic and other surgical procedures. NAROPIN is not approved for this use.
Please see Full Prescribing Information at www.naropin-us.com.
®
Using NAROPIN beyond recommended doses to increase motor block or duration of sensory block may negate its favorable cardiovascular advantages, in the event that an inadvertent intravascular injection occurs.
Like all amide-type local anesthetics, NAROPIN may be associated with adverse reactions. In clinical trials, side effects were mild and transient and may reflect the procedures, patient health status, and/or other medications used. Adverse events reported at a rate of ≥5%: hypotension, nausea, vomiting, bradycardia, fever, pain, postoperative complications, anemia, paresthesia, headache, pruritus, and back pain.
New Safety Information
There have been adverse event reports of chondrolysis in patients receiving intra-articular infusions of local anesthetics following arthroscopic and other surgical procedures. NAROPIN is not approved for this use.
Please see Full Prescribing Information at www.naropin-us.com.
NAROPIN® and logo are registered trademarks of APP Pharmaceuticals, LLC.
®and APP® are registered trademarks of APP Pharmaceuticals, LLC.
©2010, APP Pharmaceuticals, LLC. All Rights Reserved.